Nezefib (Dexamethasone Sodium Phosphate, Chloramphenicol)

Dexamethasone sodium phosphate enters ocular cells and binds to glucocorticoid receptors. This binding alters gene expression, leading to reduced production of inflammatory mediators, decreased vascular permeability, and inhibition of leukocyte migration, thereby suppressing inflammation in the eye.

The dosing regimen for Nezefib is determined by the prescribing ophthalmologist or qualified healthcare professional based on the specific condition, severity, and patient factors. The prescriber will provide detailed instructions on the number of drops, frequency, and duration of therapy.

Safety data for Nezefib in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant. Healthcare providers should discuss the risk‑benefit profile with the patient before initiating therapy.

To request Nezefib, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Nezefib uniquely combines a potent corticosteroid (dexamethasone) with a broad‑spectrum antibacterial (chloramphenicol) in a single formulation. This dual action can simplify treatment regimens compared with using separate steroid and antibiotic drops, but clinicians must consider the safety profile of each component when selecting therapy.

Nezefib should be stored at room temperature, protected from light and moisture, and kept in its original container. Do not freeze the product. Check the label for any specific storage instructions and discard any solution that appears discolored or contaminated.

Nezefib is applied as an eye drop. The prescribed number of drops is placed into the conjunctival sac of the affected eye(s) according to the healthcare provider’s instructions, typically avoiding contact with the eyelid or lashes to maintain sterility.

Serious risks include secondary ocular infection, development of cataract or glaucoma with prolonged use, and severe allergic reactions such as anaphylaxis. Patients should be monitored for signs of increased intra‑ocular pressure, visual changes, or systemic allergic symptoms and seek medical attention promptly if they occur.

Nezefib is contraindicated in patients with known hypersensitivity to dexamethasone, chloramphenicol, or any excipients in the formulation. Caution is advised in individuals with active viral eye infections, uncontrolled glaucoma, or those who are pregnant or breastfeeding without a clear benefit‑risk assessment.